Proposed Appointment of Non-Executive Director

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to announce that, subject to normal regulatory due diligence, it intends to appoint Luke Cairns as an Independent Non-Executive Director of the Company.

Luke is an experienced corporate finance professional with over 20 years of working with SMEs as both an adviser and director. He was previously Head of Corporate Finance and Joint Managing Director at Northland Capital Partners Limited, an AIM Nominated Adviser and broker firm, and has worked with many companies across several sectors and regions on a wide range of transactions, including IPOs, secondary fundraisings, corporate restructurings and takeovers.

Subsequently, Luke set up his own consultancy working with growth companies and family offices and now sits on number of private and public boards.

Dr Kevin Cox, Chair of ValiRx PLC, commented "Luke will be an excellent addition to the Board of ValiRx given his extensive experience in small companies, corporate finance and corporate governance. He will provide help and advice across all areas of the business but particularly in respect of ValiRx as a quoted company. His independent and objective views will help ensure continued progress of our strategic plans."

Dr Suzy Dilly, CEO of ValiRx PLC commented "I'm looking forward to working with Luke, drawing on his public market experience and in doing so enabling me to focus on driving the business forward in line with all our shareholders ambitions."